NCT00142103 - CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Hepatitis, Chronic Active

Interventions

DRUG

CPG10101

CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks

DRUG

Control

Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks

DRUG

CPG10101

CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks

Trial Locations (13)

10021

Pfizer Investigational Site, New York

17033

Pfizer Investigational Site, Hershey

23249

Pfizer Investigational Site, Richmond

29425

Pfizer Investigational Site, Charleston

33136

Pfizer Investigational Site, Miami

44195

Pfizer Investigational Site, Cleveland

46202

Pfizer Investigational Site, Indianapolis

60611

Pfizer Investigational Site, Chicago

64131

Pfizer Investigational Site, Kansas City

75208

Pfizer Investigational Site, Dallas

78215

Pfizer Investigational Site, San Antonio

48202-2689

Pfizer Investigational Site, Detroit

38305-2071

Pfizer Investigational Site, Jackson